Advanced renal cell carcinoma (RCC) is a type of cancer that affects the kidneys. It is one of the most common types of kidney cancer and is the most deadly type. It is estimated that about 10% of all patients with kidney cancer have advanced RCC.
Advanced RCC is usually diagnosed when the cancer has spread to other parts of the body, such as the lungs, liver, or bones. This makes it difficult to treat and the prognosis is often poor. Studies show that the five-year survival rate for advanced RCC is only 20 to 25 percent.
There are several treatment options available for advanced RCC. Surgery can be used to remove the cancerous tissue, if it has not spread too far. However, surgery is not always possible. In these cases, other treatments such as radiation, chemotherapy, and targeted therapies may be used.
Radiation therapy uses high-energy beams of radiation to destroy cancer cells. Chemotherapy drugs work by attacking the cancer cells and stopping them from growing and dividing. Targeted therapies are drugs that specifically target the cancer cells and help stop them from growing and spreading.
The outlook for advanced RCC is not good, but there are treatments that can help extend life expectancy. The most important factor in determining the prognosis is the stage of the cancer at diagnosis. The earlier the diagnosis, the better the chances of a successful outcome.
Patients with advanced RCC should also take steps to improve their overall health. This includes eating a healthy diet, exercising regularly, and avoiding smoking and excessive alcohol consumption. These activities can help to strengthen the body’s immune system and may reduce the risk of the cancer spreading.
Advanced RCC is a serious condition and its prognosis is often poor. However, there are treatments available that can help extend life expectancy and improve the quality of life for patients. It is important for patients to talk to their doctors about all the treatment options available to them and to take steps to maintain a healthy lifestyle.
Medication for treatment
Soranib 200mgTablet consists of the active ingredient Sorafenib that is indicated for advanced renal cell carcinoma (kidney cancer), advanced hepatocellular carcinoma (liver cancer) in patients ineligible for surgery and differentiated thyroid carcinoma (thyroid cancer) in patients who are not responsive to radioactive iodine therapy.
